M. Humbert (Paris, France), M. Hoeper (Hannover, Germany)
Late Breaking Abstract - Validation of the REVEAL 2.0 Risk Score with the Australian and New Zealand Pulmonary Hypertension Registry Cohort.
J. Anderson (Birtinya, Australia), E. Lau (Sydney, Australia), M. Lavender (Perth, Australia), R. Benza (Pittsburgh, United States of America), D. Celermajer (Sydney, Australia), N. Collins (Newcastle, Australia), C. Corrigan (Sydney, Australia), N. Dwyer (Hobart, Australia), J. Feenstra (Brisbane, Australia), M. Horrigan (Melbourne, Australia), D. Keating (Melbourne, Australia), E. Kotlyar (Sydney, Australia), T. Mcwilliams (Auckland, New Zealand), B. Rhodes (Christchurch, New Zealand), P. Steele (Adelaide, Australia), V. Thakkar (Liverpool, Australia), T. Williams (Melbourne, Australia), H. Whitford (Melbourne, Australia), K. Whyte (Auckland, New Zealand), R. Weintraub (Melbourne, Australia), J. Wrobel (Perth, Australia), A. Keogh (Sydney, Australia), G. Strange (Fremantle, Australia)
|    |
A prospective study comparing the repeatability and sensitivity to change of non-invasive endpoints in pulmonary arterial hypertension: the RESPIRE study
D. Kiely (Sheffied, United Kingdom), A. Swift (Sheffield, United Kingdom), M. Cogliano (Sheffield, United Kingdom), L. Kendall (Stevenage, United Kingdom), C. Oram (Sheffield, United Kingdom), D. Capener (Sheffield, United Kingdom), A. Rothman (Sheffield, United Kingdom), P. Garg (Sheffield, United Kingdom), C. Johns (Sheffield, United Kingdom), M. Austin (Sheffield, United Kingdom), J. Pickworth (Sheffield, United Kingdom), P. Hickey (Sheffield, United Kingdom), T. Kahn (Stevenage, United Kingdom), A. Lawrie (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom), F. Wilson (Stevenage, United Kingdom), J. Wild (Sheffield, United Kingdom)
| |
A dynamic prognostic model to predict survival and determine treatment goals in pulmonary arterial hypertension (PAH): the EFORT study
O. Sitbon (Le Kremlin-Bicêtre, France), P. Clerson (Roubaix, France), V. Cottin (Lyon, France), P. Degroote (Lille, France), G. Prevot (Toulouse, France), L. Savale (Le Kremlin-Bicêtre, France), X. Jaïs (Le Kremlin-Bicêtre, France), A. Chaouat (Nancy, France), C. Dromer (Bordeaux, France), A. Bourdin (Montpellier, France), S. Renard (Marseille, France), E. Bergot (Caen, France), C. Pison (Grenoble, France), F. Bauer (Rouen, France), C. Dauphin (Clermont Ferrand, France), M. Reynaud Gaubert (Marseille, France), D. Montani (Le Kremlin-Bicêtre, France), G. Simonneau (Le Kremlin-Bicêtre, France), M. Humbert (Le Kremlin-Bicêtre, France)
| |
Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD)
S. Ramjug (Manchester, United Kingdom), C. Billings (Sheffield, United Kingdom), S. Bowater (Birmingham, United Kingdom), A. Charalampopoulos (Sheffield, United Kingdom), P. Clift (Birmingham, United Kingdom), C. Elliot (Sheffield, United Kingdom), J. Hurdman (Sheffield, United Kingdom), P. Jenkins (Liverpool, United Kingdom), D. Kiely (Sheffield, United Kingdom), R. Lewis (Sheffield, United Kingdom), J. Oliver (Leeds, United Kingdom), I. Sabroe (Sheffield, United Kingdom), R. Condliffe (Sheffield, United Kingdom)
| |
Risk assessment and prognosis in patients with pulmonary arterial hypertension receiving intravenous treprostinil
K. Olsson (Hannover, Germany), M. Richter (Gießen , Germany), J. Kamp (Hannover, Germany), H. Gall (Gießen, Germany), A. Heine (Greifswald, Germany), H. Ghofrani (Greifswald, Germany), J. Fuge (Hannover, Germany), R. Ewert (Greifswald, Germany), M. Hoeper (Greifswald, Germany)
| |
Serum endostatin as a genetically-influenced biomarker in PAH
C. Simpson (Baltimore, United States of America), R. Damico (Baltimore, United States of America), P. Hassoun (Baltimore, United States of America), L. Martin (Cincinnati, United States of America), J. Yang (Baltimore, United States of America), M. Nies (Baltimore, United States of America), R. Vaidya (Baltimore, United States of America), S. Brandal (Baltimore, United States of America), M. Pauciulo (Cincinnati, United States of America), E. Austin (Nashville, United States of America), D. Ivy (Aurora, United States of America), W. Nichols (Aurora, United States of America), A. Everett (Baltimore, United States of America)
| |
Asymmetric dimethylarginine (ADMA) to monitor treatments of pulmonary hypertension
N. Skoro-Sajer (Vienna, Austria), V. Probst (Vienna, Austria), R. Sadushi-Kolici (Vienna, Austria), C. Gerges (Vienna, Austria), I. Campean (Vienna, Austria), I. Lang (Vienna, Austria)
| |
The change of lung diffusion capacity does not influence the prognosis in patients with pulmonary arterial hypertension associated with systemic sclerosis.
A. Volkov (Moscow, Russian Federation), E. Nikolaeva (Moscow, Russian Federation), N. Yudkina (Moscow, Russian Federation), T. Martynyuk (Moscow, Russian Federation)
| |